Optimize drug therapy with respect to the patient’s genotype, ensuring maximum drug efficiency with minimal adverse effects.
Throughout the history of drug development, treatments were tested and approved based on what works for most people. As medical and biopharmaceutical technologies advance, however, the healthcare community has come to understand that each patient is unique. We can achieve far more effective outcomes by treating them as individuals.
A deeper understanding of different groups and populations improves pharmacovigilance, clinical trials, and the real-world therapeutic efficiency of drugs.
Pharmacogenetic studies benefit clinical trials in 3 ways:
Optimizing pharmacovigilance by identifying the percentage of individuals at risk of adverse drug reactions
Recommending therapeutic dosage regimens of specific drugs for specific populations
Improving clinical trials by stratifying populations based on genetic differences in ethnic and cultural identities and their susceptibility to drug activity
In the US alone there are an estimated 100 million adults suffering from chronic pain.Learn how Pharmacogenomics help assess the safety and efficacy of treatments
Personalized therapy is closer than we think. It’s in our DNA. Now is the time to embrace it.
Andrew Purchase, Director, Patient Safety Operations, PV and Patient Safety
When to engage our Pharmacogenomics experts in your product’s lifecycle:
PRA is committed to providing the most effective treatment options for patients. The pharmacogenomics group has the advantage of working across a wider range of therapeutic targets than any of our clients, which allows us to offer a broad range of experience and knowledge. By contributing to the acceleration of personalized medicine and individualized treatments, pharmacogenomics helps us as an industry become more patient-centric, focusing on a whole individual rather than an entire patient population.
Local Representation: What Clinical Trial Sponsors Need to Know
In this white paper, best practices are described as well as required Sponsor/Local Representative agreement areas. It is important that major…
PV Nugget #6 Literature Surveillance
Literature is regarded as a significant source of information in the monitoring of a medicinal product, its safety profile, and benefit-risk balance.…
Pharmacovigilance & Patient Safety Solutions in Response to COVID-19
The COVID-19 pandemic poses a critical challenge to individuals, caregivers and healthcare systems worldwide. This challenge extends directly to the…